Hussman Strategic Advisors Inc. Grows Stock Holdings in Phibro Animal Health Corporation (NASDAQ:PAHC)

Hussman Strategic Advisors Inc. raised its stake in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 20.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,000 shares of the company's stock after buying an additional 21,000 shares during the period. Hussman Strategic Advisors Inc. owned about 0.31% of Phibro Animal Health worth $2,691,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Man Group plc purchased a new stake in Phibro Animal Health in the 4th quarter valued at about $501,000. GAMMA Investing LLC lifted its position in shares of Phibro Animal Health by 2,011.4% in the 1st quarter. GAMMA Investing LLC now owns 36,718 shares of the company's stock worth $784,000 after purchasing an additional 34,979 shares during the period. Lazard Asset Management LLC lifted its position in shares of Phibro Animal Health by 2,739.7% in the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after purchasing an additional 1,589 shares during the period. Nuveen Asset Management LLC lifted its position in shares of Phibro Animal Health by 21.4% in the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company's stock worth $12,348,000 after purchasing an additional 103,618 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Phibro Animal Health by 37.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 62,566 shares of the company's stock worth $1,314,000 after purchasing an additional 16,917 shares during the period. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Stock Performance

PAHC stock traded down $0.13 during midday trading on Friday, hitting $29.61. 21,081 shares of the stock traded hands, compared to its average volume of 222,757. The firm has a market cap of $1.20 billion, a P/E ratio of 38.00, a PEG ratio of 0.51 and a beta of 0.75. The company has a debt-to-equity ratio of 2.67, a current ratio of 2.91 and a quick ratio of 1.23. The stock's fifty day simple moving average is $25.48 and its 200-day simple moving average is $22.64. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $31.80.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.11. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. The business had revenue of $347.80 million for the quarter, compared to analyst estimates of $352.41 million. On average, analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Wednesday, June 4th were paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.62%. The ex-dividend date was Wednesday, June 4th. Phibro Animal Health's dividend payout ratio is currently 61.54%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on PAHC shares. Morgan Stanley set a $26.00 price target on shares of Phibro Animal Health and gave the stock an "equal weight" rating in a research report on Wednesday, June 25th. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their target price for the company from $25.00 to $35.00 in a research report on Monday, July 7th. Wall Street Zen raised shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price for the company in a research report on Monday, June 16th. Finally, BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Phibro Animal Health presently has a consensus rating of "Hold" and an average price target of $24.40.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.